Document Detail


ACS Chemical Neuroscience Molecule Spotlight on RG1678.
MedLine Citation:
PMID:  22860161     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Abstract/OtherAbstract:
RG1678 is a glycine transporter-1 inhibitor currently in Phase III trials for the treatment of the negative symptoms of schizophrenia and is being developed by Roche (in combination with Chugai). Recent Phase II data shows that RG1678 is effective in reducing the negative symptoms when given in combination with second generation antipsychotics.
Authors:
Corey R Hopkins
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  ACS chemical neuroscience     Volume:  2     ISSN:  1948-7193     ISO Abbreviation:  ACS Chem Neurosci     Publication Date:  2011 Dec 
Date Detail:
Created Date:  2012-08-03     Completed Date:  2012-08-23     Revised Date:  2012-12-21    
Medline Journal Info:
Nlm Unique ID:  101525337     Medline TA:  ACS Chem Neurosci     Country:  United States    
Other Details:
Languages:  eng     Pagination:  685-6     Citation Subset:  -    
Affiliation:
Department of Pharmacology and Chemistry, Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Vanderbilt University , Nashville, Tennessee 37232-6600, United States.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Phosphorylation of ?-Synuclein at Y125 and S129 alters its metal binding properties: implications fo...
Next Document:  Detection of multiple sclerosis from exhaled breath using bilayers of polycyclic aromatic hydrocarbo...